CEO Dr. Essam Hamza Shares Insights on Penny Queen’s Show, Stock Therapy

Transforming Healthcare: Dr. Essam Hamza Discusses the Revolutionary Global Library of Medicine and Its New Pharmacy Application

Editorial Team (ET)July 2, 2025

In a recent episode of Stock Therapy with Penny Queen, Dr. Essam Hamza, CEO of Treatment.com, discussed the latest advancements in their Global Library of Medicine (GLM) and its new pharmacy application. The interview delved into the significance of GLM in modern healthcare and its impact on the roles of allied professionals like pharmacists.

Treatment.com and Dr. Essam Hamza

Treatment.com, under the leadership of Dr. Essam Hamza, is at the cutting edge of integrating AI into healthcare. The company’s flagship product, the Global Library of Medicine (GLM), is designed to assist healthcare practitioners in diagnosing and treating a wide range of diseases.

The Global Library of Medicine (GLM)

The GLM is a comprehensive database that includes over a thousand diseases and tens of thousands of symptoms and risk factors. It uses a proprietary algorithm to mimic the diagnostic process of experienced doctors, ensuring accurate and efficient patient care.

Pharmacy Application of GLM

Dr. Hamza highlighted the recent launch of the pharmacy application of GLM, a strategic move aimed at empowering pharmacists. This application allows pharmacists to take patient histories, diagnose common conditions, and recommend treatments independently, thus alleviating the burden on doctors and enhancing patient care.

Role of Allied Professionals

The interview emphasized the growing role of allied professionals in healthcare, particularly pharmacists and nurses. With rising healthcare costs and limited access to providers, these professionals are increasingly taking on diagnostic and treatment responsibilities. The GLM supports them by streamlining administrative tasks and enhancing diagnostic accuracy.

Addressing Challenges for Pharmacists

One of the significant challenges for pharmacists is the administrative burden associated with their expanded roles. The GLM automates many of these tasks, reducing the time spent on documentation and increasing diagnostic confidence. This, in turn, mitigates liability issues and allows pharmacists to focus more on patient care.

Adoption and Impact of GLM

Dr. Hamza shared that GLM has already been used in over 1 million assessments across Canada, with plans for further expansion. This widespread adoption demonstrates the system’s effectiveness in real-world settings and its potential to transform healthcare delivery globally.

Generative AI vs. Curative AI

The discussion also touched on the risks associated with generative AI in healthcare, such as providing inaccurate or misleading information. In contrast, GLM’s curative AI offers a reliable and controlled approach to diagnostics and treatment recommendations, integrating the best of both AI technologies.

Real-World Application: Diagnosing Bladder Infections

A real-world example provided by Dr. Hamza illustrated how GLM facilitates the early diagnosis and treatment of common conditions like bladder infections. By enabling pharmacists to handle these cases, GLM helps prevent complications and reduces the need for urgent care visits, resulting in significant cost savings.

From an investor’s viewpoint, Treatment.com has shown strong stock performance, reflecting confidence in GLM’s potential. With ongoing developments and expanding adoption, the company is poised for significant growth, making it an attractive investment opportunity.

Conclusion

In conclusion, Treatment.com’s Global Library of Medicine represents a groundbreaking advancement in healthcare. By empowering pharmacists and other allied professionals, it addresses critical issues of cost, access, and quality of care. With its recent pharmacy application, GLM is set to revolutionize how minor ailments are managed, ensuring better health outcomes for patients worldwide.

Treatment.AI

Disclaimer

This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.